DK571484D0 - SUBSTITUTED ETHYLENDIAMINE DERIVATIVES AND THEIR PREPARATION AND USE - Google Patents

SUBSTITUTED ETHYLENDIAMINE DERIVATIVES AND THEIR PREPARATION AND USE

Info

Publication number
DK571484D0
DK571484D0 DK571484A DK571484A DK571484D0 DK 571484 D0 DK571484 D0 DK 571484D0 DK 571484 A DK571484 A DK 571484A DK 571484 A DK571484 A DK 571484A DK 571484 D0 DK571484 D0 DK 571484D0
Authority
DK
Denmark
Prior art keywords
ethylendiamine
derivatives
substituted
preparation
substituted ethylendiamine
Prior art date
Application number
DK571484A
Other languages
Danish (da)
Other versions
DK571484A (en
Inventor
Vittorio Rasetti
Peter Buehlmayer
Walter Fuhrer
Rudolf Heinrich Andreatta
Anthony Caselli
Ulrich Renner
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK571484D0 publication Critical patent/DK571484D0/en
Publication of DK571484A publication Critical patent/DK571484A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
DK571484A 1983-12-01 1984-11-30 SUBSTITUTED ETHYLENDIAMINE DERIVATIVES AND THEIR PREPARATION AND USE DK571484A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH643683 1983-12-01

Publications (2)

Publication Number Publication Date
DK571484D0 true DK571484D0 (en) 1984-11-30
DK571484A DK571484A (en) 1985-06-02

Family

ID=4309613

Family Applications (1)

Application Number Title Priority Date Filing Date
DK571484A DK571484A (en) 1983-12-01 1984-11-30 SUBSTITUTED ETHYLENDIAMINE DERIVATIVES AND THEIR PREPARATION AND USE

Country Status (6)

Country Link
EP (1) EP0144290A3 (en)
JP (1) JPS60136595A (en)
AU (1) AU3609484A (en)
DK (1) DK571484A (en)
ES (1) ES8701142A1 (en)
GR (1) GR81124B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88400C (en) * 1984-08-06 1993-05-10 Upjohn Co FRAMEWORK FOR THE FRAME STATION INHIBITION OF PEPTIDER
JPH05501879A (en) * 1989-10-27 1993-04-08 ジ・アップジョン・カンパニー Methods of treating HIV and other retroviruses and compounds useful therein
FR2711990B1 (en) * 1993-11-05 1995-12-08 Exsymol Sa Pseudodipeptide product having an imidazole group, and therapeutic, cosmetological and agrifood applications.
AU3184395A (en) * 1994-08-05 1996-03-04 Warwick International Group Limited Bleach activators
JP4484897B2 (en) * 1995-12-08 2010-06-16 生化学工業株式会社 Method for producing amino alcohol derivative
GB9727123D0 (en) * 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
EP1196386A2 (en) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
ES2380904T3 (en) * 2005-01-26 2012-05-21 Allergan, Inc. Pharmaceutical compositions that have an analgesic effect and contain 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds
DK2032134T3 (en) 2006-05-09 2015-09-28 Genzyme Corp Processes for the treatment of fatty liver disease which includes inhibition of glucosphingolipidsyntese
EP2594565B1 (en) * 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
JP5896601B2 (en) 2007-10-05 2016-03-30 ジェンザイム コーポレーション Method for treating polycystic kidney disease using ceramide derivatives
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
RU2578947C2 (en) 2008-10-03 2016-03-27 Джензайм Корпорейшн 2-acylaminopropanol glucosylceramide synthase inhibitors
AU2018328015A1 (en) * 2017-09-05 2020-03-05 Merck Sharp & Dohme Corp. Compounds for reducing the viscosity of biological formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198398A (en) * 1977-07-12 1980-04-15 Derek Hudson Enkephalin analogues
US4145337A (en) * 1977-10-11 1979-03-20 Hoffmann-La Roche Inc. Aminoethylglycine containing polypeptides
GB2058077B (en) * 1979-06-08 1983-03-09 Szelke M Enkephalin analogues
NO812612L (en) * 1980-08-06 1982-02-08 Ferring Pharma Ltd ENZYME inhibitor.
CA1245217A (en) * 1981-12-10 1988-11-22 Joshua S. Boger Renin inhibitory peptides having phe su13 xx deletion
WO1984003044A1 (en) * 1983-02-07 1984-08-16 Ferring Ab Enzyme inhibitors
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres

Also Published As

Publication number Publication date
GR81124B (en) 1985-03-26
ES8701142A1 (en) 1986-11-16
EP0144290A2 (en) 1985-06-12
JPS60136595A (en) 1985-07-20
AU3609484A (en) 1985-06-06
ES538172A0 (en) 1986-11-16
EP0144290A3 (en) 1987-05-27
DK571484A (en) 1985-06-02

Similar Documents

Publication Publication Date Title
DK554784A (en) SUBSTITUTED 5-AMINO-4-HYDROXYVALE RELEASE DERIVATIVES AND THEIR PREPARATION AND USE
DK559985A (en) 13BETA-MILBEMYCINE DERIVATIVES AND THEIR PREPARATION AND USE
DK211582A (en) ARYLPHENYLETHER DERIVATIVES AND THEIR PREPARATION AND USE
DK289886A (en) SUBSTITUTED 3-PHENYL-4-CYANOPYRROL DERIVATIVES AND THEIR PREPARATION AND USE
DK410384A (en) N- (2-NITROPHENYL) -4-AMINOPYRIMIDINE DERIVATIVES AND THEIR PREPARATION AND USE
DK41484A (en) BETA-PHENETHANOLAMINES AND THEIR USE
DK317588A (en) 2-ANILINO-PYRIMIDINE DERIVATIVES AND THEIR PREPARATION AND USE
DK571484A (en) SUBSTITUTED ETHYLENDIAMINE DERIVATIVES AND THEIR PREPARATION AND USE
DK578185D0 (en) 13BETA-MILBEMYCINE DERIVATIVES AND THEIR PREPARATION AND USE
DK614084A (en) MILBEMYCIM DERIVATIVES AND THEIR PREPARATION AND USE
DK35884D0 (en) LACTAMPEPTIDES AND THEIR PREPARATION AND USE
DK614384A (en) SUBSTITUTED IMIDAZOLES AND THEIR PREPARATION AND USE
DK294684A (en) N-ALKYLERED 3-PHENYL-4-CYANOPYRROL DERIVATIVES AND THEIR PREPARATION AND USE
DK297082A (en) SUBSTITUTED 1-AZOLYL-2-HYDROXY ALKANDER DERIVATIVES AND THEIR PREPARATION AND USE
DK558484A (en) MILBEMYCINE DERIVATIVES AND THEIR PREPARATION AND USE
DK45188A (en) SUBSTITUTED AMINDER DERIVATIVES AND THEIR USE
DK537785A (en) FLAVOLIGNAN DERIVATIVES AND THEIR PREPARATION AND USE
DK297182A (en) SUBSTITUTED 2-HYDROXY-3-AZOLYL PROPANDER DERIVATIVES AND THEIR PREPARATION AND USE
DK189584D0 (en) (5ALFA) -20-SPIROX-1-EN-3-ONER AND THEIR PREPARATION AND USE
DK419084A (en) 2-AMINOMETHYL-2-PENEM COMPOUNDS AND THEIR PREPARATION AND USE
DK393285D0 (en) SUBSTITUTED CARBONYLPHENYLSULPHONYLGUANIDINES AND THEIR PREPARATION AND USE
DK236585A (en) ACYLED HEXOSIDE DERIVATIVES AND THEIR PREPARATION AND USE
DK35984A (en) LACTAMPEPTIDES AND THEIR PREPARATION AND USE
DK422685D0 (en) BENZAZOLD DERIVATIVES AND THEIR PREPARATION AND USE
DK153285D0 (en) BENZODIOXOLD DERIVATIVES AND THEIR PREPARATION AND USE

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment